ClinicalTrials.gg
CompletedNCT06525311Updated May 23, 2025

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

A Phase 1 interventional study of K-808 in Primary Biliary Cholangitis and Compensated Cirrhosis, sponsored by Kowa Research Institute, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
53rd of 65
17 · median 46
Started
2024
with 6 others
Phase 1
7 of 83
1 open now
Registered
74th of 83
by date
Lead sponsor
2 of 83
Kowa Research Institute, Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 53rd largest by enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 7 in phase 1, and was the 74th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.

03

Conditions studied

  • Primary Biliary Cholangitis
  • Compensated Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a PBC diagnosis as demonstrated by the presence of ≥2 of the following three diagnostic criteria (Lindor et al, 2019; Hirschfield et al, 2017):

    1. History of ALP above for at least 6 months
    2. History of positive antimitochondrial antibody (AMA) titer or positive PBC-specific antinuclear antibody (ANA) titers
    3. Historical liver consistent with PBC
  • Has PBC with cirrhosis grade A (well-compensated disease; score 5 to 6) at Screening. Group 2 (PBC w/ CIRR CP-A) only
  • Male or female participant is ≥18 years of age at consent.
  • Able to understand and comply with study requirements and procedures and provide written .
  • Meet all other inclusion criteria outlined in the clinical study protocol.

Exclusion criteria

Exclusion Criteria:

  • Female subject of who is known to be pregnant, has a positive pregnancy test (serum test, or urine test that is confirmed by a positive serum pregnancy test), or is lactating and breastfeeding, or planning to become pregnant or breastfeed during the study.
  • Subject has had ongoing conditions that may affect drug absorption such as gastroparesis, intestinal obstruction, severe gastritis, severe gastric reflux syndrome, conditions causing frequent vomiting and/or diarrhea.
  • Subject who has participated in another drug, biologic, or medical device study within five half-lives of the agent (or within 8 weeks when half-life is unknown) prior to the first dose of study drug, or prior participation in an investigational antibody drug study within 6 months prior to the first dose of study drug. Participation in noninterventional studies (eg, observational studies, registries) is allowed.
  • Meet any other exclusion criteria outlined in the clinical study protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    PBC w/o CIRR

    K-808 single dose followed by multiple-dose treatment period.

    Drug: K-808

  • Experimental
    PBC w/ CIRR CP-A

    K-808 single dose followed by optional multiple-dose treatment period.

    Drug: K-808

Interventions

  • DrugK-808

    K-808 single or multi dose extended-release tablets

    Also known as: Pemafibrate

06

What researchers measure

Primary outcomes

  1. PK parameters after a single dose of K-808: Area under the curve from 0 to infinity (AUC0-inf)

    Time frame: Day 1 - Day 3

  2. PK parameters after a single dose of K-808: Area under the curve from time 0 to last quantifiable time (AUC0-t)

    Time frame: Day 1 to Day 3

  3. PK parameters after a single dose of K-808: Observed maximum plasma concentration (Cmax)

    Time frame: Day 1 to Day 3

  4. PK parameters after a single dose of K-808: Time to reach observed maximum plasma concentration (Tmax)

    Time frame: Day 1 to Day 3

  5. PK parameters after a single dose of K-808: kel

    Time frame: Day 1 to Day 3

  6. PK parameters after a single dose of K-808: Apparent first-order terminal elimination half-life (t½)

    Time frame: Day 1 to Day 3.

  7. PK parameters after a single dose of K-808: Apparent total volume of distribution estimated based on the terminal phase (Vd/F)

    Time frame: Day 1 to Day 3

  8. PK parameters after a single dose of K-808: Apparent plasma clearance after extravascular administration (CL/F)

    Time frame: Day 1 to Day 3

  9. PK parameters after a single dose of K-808: Mean resistance time from time 0 to last measurable concentration (MRT0-t)

    Time frame: Day 1 to Day 3

  10. PK parameters after a single dose of K-808: MRT from time 0 extrapolated to infinity (MRT0-inf)

    Time frame: Day 1 to Day 3

  11. Trough concentrations after multiple dosing of K-808

    Time frame: Day 4 - Day 6

  12. PK parameters at steady state after multiple dosing of K-808: Area under the curve over the dosing interval (AUC0-tau)

    Time frame: Day 6 to Day 8

  13. PK parameters at steady state after multiple dosing of K-808: Cmax

    Time frame: Day 6 to Day 8

  14. PK parameters at steady state after multiple dosing of K-808: Tmax

    Time frame: Day 6 to Day 8

  15. PK parameters at steady state after multiple dosing of K-808: kel

    Time frame: Day 6 to Day 8

  16. PK parameters at steady state after multiple dosing of K-808: t½

    Time frame: Day 6 to Day 8

  17. PK parameters at steady state after multiple dosing of K-808: Vd,ss/F at steady state

    Time frame: Day 6 to Day 8

  18. PK parameters at steady state after multiple dosing of K-808: CLss/F at steady state

    Time frame: Day 6 to Day 8

  19. PK parameters at steady state after multiple dosing of K-808: MRT at steady state (MRTss)

    Time frame: Day 6 to Day 8

  20. PK parameters at steady state after multiple dosing of K-808: Observed accumulation ratio based on the AUC (RobsAUC)

    Time frame: Day 6 to Day 8

Secondary outcomes

  1. PK parameters of K-808 metabolites after a single dose: AUC0-inf

    Time frame: Day 1 - Day 3

  2. PK parameters of K-808 metabolites after a single dose: AUC0-t

    Time frame: Day 1 to Day 3

  3. PK parameters of K-808 metabolites after a single dose: Cmax

    Time frame: Day 1 to Day 3

  4. PK parameters of K-808 metabolites after a single dose: Tmax

    Time frame: Day 1 to Day 3

  5. PK parameters of K-808 metabolites after a single dose: kel

    Time frame: Day 1 to Day 3

  6. PK parameters of K-808 metabolites after a single dose: t½

    Time frame: Day 1 to Day 3

  7. PK parameters of K-808 metabolites after a single dose: MRT0-t

    Time frame: Day 1 to Day 3

  8. PK parameters of K-808 metabolites after a single dose: MRT0-inf

    Time frame: Day 1 to Day 3

  9. PK parameters at steady state after multiple dosing of K-808: AUC0- tau

    Time frame: Day 6 to Day 8

  10. PK parameters at steady state after multiple dosing of K-808: Cmax

    Time frame: Day 6 to Day 8

  11. PK parameters at steady state after multiple dosing of K-808: Tmax

    Time frame: Day 6 to Day 8

  12. PK parameters at steady state after multiple dosing of K-808: kel

    Time frame: Day 6 to Day 8

  13. PK parameters at steady state after multiple dosing of K-808: t½

    Time frame: Day 6 to Day 8

  14. PK parameters at steady state after multiple dosing of K-808: (MRTss)

    Time frame: Day 6 to Day 8

  15. PK parameters at steady state after multiple dosing of K-808: (RobsAUC)

    Time frame: Day 6 to Day 8

  16. Trough concentrations after multiple dosing of K-808

    Time frame: Day 4 to Day 6

  17. To assess the safety and tolerability of K-808

    Time frame: 5 Weeks

07

Study locations

10 sites
  • Arizona Liver Health
    Chandler, Arizona 85225, United States
  • Southern California Research Center, Inc
    Coronado, California 92118, United States
  • Indiana University School of Medicine - Indianapolis
    Indianapolis, Indiana 46202, United States
  • Houston Research Institute
    Houston, Texas 77079, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 782329, United States
  • 303
    Fukuoka, Japan
  • 302
    Kita-gun, Japan
  • 304
    Shinjuku-ku, Japan
  • 301
    Yufu, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2025, 5 months.

Of 15 phase 1 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 29, 2024
StartActual
Oct 1, 2024
Primary completionActual
Mar 12, 2025
CompletionActual
Apr 9, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06525311
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Oct 1, 2024
Primary completion
Mar 12, 2025
Completion
Apr 9, 2025
Last update
May 23, 2025

Study contacts

Sara Neville, MD
study director · Kowa Research Institute, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion